CLINICAL TRIALS PROFILE FOR KISQALI
✉ Email this page to a colleague
All Clinical Trials for Kisqali
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02035813 ↗ | DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). | Recruiting | Prof. W. Janni | Phase 2 | 2014-01-01 | Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value of CTCs in MBC is well understood, the role of both CTC prevalence and CTC phenotype in predicting treatment response needs further investigation. DETECT IV is a prospective, multicenter, open-label, phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). Additional research on CTC dynamics and characteristics will provide a better understanding of the prognostic and predictive value of CTCs and is one step into a more personalized therapy for MBC. |
| NCT02344472 ↗ | Detect V / CHEVENDO (Chemo vs. Endo) | Recruiting | Celgene Corporation | Phase 3 | 2015-09-01 | Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer. |
| NCT02344472 ↗ | Detect V / CHEVENDO (Chemo vs. Endo) | Recruiting | DETECT study group | Phase 3 | 2015-09-01 | Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer. |
| NCT02344472 ↗ | Detect V / CHEVENDO (Chemo vs. Endo) | Recruiting | Eisai GmbH | Phase 3 | 2015-09-01 | Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer. |
| NCT02344472 ↗ | Detect V / CHEVENDO (Chemo vs. Endo) | Recruiting | Novartis Pharmaceuticals | Phase 3 | 2015-09-01 | Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer. |
| NCT02344472 ↗ | Detect V / CHEVENDO (Chemo vs. Endo) | Recruiting | Roche Pharma AG | Phase 3 | 2015-09-01 | Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Kisqali
Condition Name
Clinical Trial Locations for Kisqali
Trials by Country
Clinical Trial Progress for Kisqali
Clinical Trial Phase
Clinical Trial Sponsors for Kisqali
Sponsor Name
